Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Capmatinib plus spartalizumab versus docetaxel in previously treated advanced non-small cell lung cancer
NL-OMON48017Phase 2Active, not recruiting
- Sponsor
- Novartis
- Start
- May 2019
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of capmatinib, spartalizumab and docetaxel in non-small cell lung cancer (NSCLC) (3 arms), sponsored by Novartis. Primary endpoints: Safety and tolerability and Preliminary efficacy. Started May 2019; status: active, not recruiting.
02
Drugs
capmatinibspartalizumabdocetaxel
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON48017.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON48017.